Team Startupcity

·Scopio Labs secures $10M Series D funding from Viola Growth

· Funds to accelerate AI-based CBM analyzer development

· Demo set for ADLM 2025; regulatory approval pending

Scopio Labs, one of the top AI-powered healthtech companies, has secured another $10 million in its Series D round, led by Viola Growth, taking its total Series D funding to $52 million.

The new funds will drive the development of Scopio's Breakthrough technology  the Complete Blood Morphology (CBM) Analyzer. The advanced system is aimed at automating peripheral blood smear analysis, a process that usually involves time-consuming manual expertise.

Also Read- Pine Labs to File DRHP for Rs 6,000 Crore IPO as It Seeks Strategic Move to Indian Market

Through the integration of AI algorithms with ultra-high-resolution imaging, Scopio seeks to accelerate blood diagnostics, make it more scalable and accessible, particularly in under-resourced and high-demand clinical environments.

Although the CBM system is not yet approved for in vitro diagnostic purposes and continues to be developed, Scopio is set to unveil it at the ADLM 2025 Annual Conference in Chicago later this month  giving the clinical lab community a sneak preview of what may be a landmark advancement in automating hematology.

As worldwide demand increases for quicker and more precise diagnostics, this funding injection positions Scopio Labs well to be a leading disruptor in digital hematology and laboratory automation.